Raised Liver Enzymes on Your Report — What It Means

A raised SGPT (ALT) or SGOT (AST) result during immunotherapy usually means the liver is inflamed — most often immune-related hepatitis, where an overactive immune response affects liver cells rather than the cancer itself. NCCN and ASCO management guidance for checkpoint inhibitor immunotherapy lists this as one of the immune-related adverse events (irAEs) that routine blood tests are designed to pick up. Your oncology team compares your value to the upper limit of normal (ULN) for your lab and looks at how many times above that limit you are — that multiple, not the raw number alone, guides what happens next. It's rarely something you'll feel; it's usually found on a scheduled test.

NCCN and ASCO irAE management guidance grades the rise by how many times above the upper limit of normal (ULN) your SGPT/SGOT are: roughly up to 3x ULN (mild) usually means immunotherapy continues with closer monitoring; more than 3x to 5x ULN (moderate) typically means immunotherapy is paused while a steroid course is considered; more than 5x ULN, or bilirubin rising alongside the enzymes, is treated as severe and needs urgent same-day assessment, usually with immunotherapy stopped and a liver specialist involved. Your own oncologist applies this alongside your full clinical picture — these are typical bands, not a fixed rule that overrides their judgement.

For most patients, no. Enzyme levels typically move back towards normal once the immune reaction is treated, though how long that takes depends on how high they rose and how quickly it was caught. Mild (Grade 1) rises often settle with continued monitoring alone; higher grades usually need immunotherapy paused and, in many cases, a steroid course before levels normalise. A small proportion of patients are left with some residual change in liver function after a severe reaction, which is one reason oncology teams push for same-day reporting rather than waiting to see if a rise settles on its own.

No. A rise in SGPT or SGOT can also come from an unrelated medicine, alcohol, a pre-existing liver condition, or a viral infection — which is exactly why a hepatitis screen and a review of your other medicines are part of the same-day work-up, not an afterthought. Immune-related hepatitis is diagnosed by ruling these other causes out, alongside the pattern and timing of the rise relative to your immunotherapy doses. That's also why the same visible or blood-test pattern is investigated properly each time rather than assumed.

Your oncology team will usually repeat the liver function tests (LFTs) to confirm the result, then order a hepatitis screen and review your other medicines and alcohol intake to rule out non-immune causes. Bilirubin is checked alongside SGPT/SGOT, because a rise there points to more significant liver involvement. In some cases, an ultrasound is done to rule out gallstones or other structural causes. Together, these results let your team grade the reaction accurately and decide whether monitoring, a paused dose, or steroid medication is the right next step.

Often, yes — a mild (Grade 1) rise, up to roughly three times the upper limit of normal, is usually managed by continuing immunotherapy with closer monitoring and more frequent repeat blood tests, rather than stopping treatment outright. This is a decision your treating oncologist makes using your full report and trend over time, not the single number in isolation. If the level climbs further on a repeat test, or bilirubin starts rising too, the plan is reassessed immediately — which is why follow-up testing matters as much as the first result.